High-dose melphalan with stem cell transplantation (HDM/SCT) extends survival and induces hematologic and clinical responses in patients with light chain (AL) amyloidosis. Eighty percent of melphalan is bound to plasma proteins (60% albumin-bound). We hypothesized that patients with profound hypoalbuminemia have a greater free melphalan fraction and more toxicity. Patients with AL amyloidosis treated with HDM/SCT between 2011 and 2014 with severe hypoalbuminemia (SH), defined as serum albumin ⩽ 2 g/dL were studied retrospectively. Sixteen patients with SH were identified. Forty-one patients without severe hypoalbuminemia (WSH) treated between 2011 and 2012 served as control. The incidence of acute renal failure requiring hemodialysis was 25% among patients with SH, compared with 5% among patients WSH (P = 0.05). Not all patients who needed dialysis required it long term; 6.25% for SH and 2.44% for WSH (P = 0.49). The rates of grade 3 or 4 febrile neutropenia and gastrointestinal toxicities were not significantly different between the groups. Engraftment kinetics were similar for both groups. Grade 4 renal toxicity and grade 3 lightheadedness were more frequent in patients with SH undergoing HDM/SCT for AL amyloidosis. Further studies into the mechanism of increased renal toxicity in patients with SH are warranted.
INTRODUCTION
The amyloidoses are a group of diseases where insoluble toxic protein aggregates are deposited in tissues and vital organs. Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis, where the amyloidogenic protein is an Ig light chain or light chain fragment produced by a clonal population of plasma cells in the bone marrow. 2 Eradicating the small plasma cell clone by chemotherapy can arrest damage and may result in improvement of the affected organs. One of the major advances in the treatment of AL amyloidosis is the utilization of high-dose melphalan with autologous hematopoietic stem cell transplantation (HDM/SCT). This approach to treatment has been shown to extend survival and to induce hematologic and clinical responses in selected patients, even in those with cardiac involvement. [3] [4] [5] [6] [7] Melphalan, first synthesized by Bergel and Stock in 1953, is a non-cell-cycle specific bifunctional (interstrand or intrastand) alkylating agent. 8 Most of this drug is eliminated by renal excretion. Melphalan also undergoes spontaneous degradation to non-cytotoxic active metabolites, but this occurs to a much smaller degree because of its binding to plasma proteins. 9, 10 In vitro, melphalan is 60% bound to albumin. 11 The kidneys are frequently involved in AL amyloidosis, 12 with patients often presenting with nephrotic syndrome. 2 Severe hypoalbuminemia (SH) from nephrotic syndrome may result in higher free melphalan levels, and therefore increased toxicity. The most common toxicities of HDM include profound myelosuppression, nausea and vomiting, mucositis, and diarrhea. 8 The objective of this study was to evaluate whether patients with AL amyloidosis and SH treated with HDM/SCT experience more treatment-related toxicity with respect to myelosuppression and gastrointestinal toxicities compared with patients without severe hypoalbuminemia (WSH). We hypothesized that patients with SH have decreased melphalan clearance, increased unbound drug levels and are therefore at higher risk of melphalan toxicity.
MATERIALS AND METHODS

Study design and participants
In this retrospective single center observational study, we analyzed consecutive patients with AL amyloidosis and SH treated with HDM/SCT between January 2011 and December 2014 at the Boston Medical Center (BMC). SH was defined as a serum albumin level of 2 g/dL or less prior to admission to the SCT program. Patient data were extracted from the stem cell transplant database and the hospital's electronic medical record. AL amyloidosis patients WSH treated with HDM/SCT between January 2011 and December 2012 were identified and served as control. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4). This study was approved by the BMC institutional review board. All study subjects signed an informed consent in accordance to the Declaration of Helsinki.
For the HDM/SCT procedure, all patients first underwent stem cell mobilization with granulocyte colony-stimulating factor followed by stem cell collection. Afterwards, HDM, dosed at either 200 mg/m 2 or 140 mg/m 2 , was given intravenously over 2 days in equally divided doses (days − 3 and − 2). Stem cell infusion was then performed on day 0. The HDM/SCT procedure was performed in the outpatient setting. Patients underwent daily evaluations in the SCT clinic, and were admitted to the hematology inpatient service for complications. 1 
Statistical analysis
Fisher's exact test was used to compare proportions. The Kruskal-Wallis rank sum test was used to compare means as the data did not follow a normal distribution. A P value of o 0.05 was considered statistically significant in this study.
RESULTS
Baseline characteristics
Of the 84 patients with AL amyloidosis who underwent HDM/SCT between January 2011 and December 2014, 16 patients (19.05%) with SH were identified. Forty-one patients WSH treated between January 2011 and December 2012 served as control. Baseline characteristics, including age, sex, serum albumin level, creatinine clearance, proteinuria, cardiac biomarkers, hemoglobin and organ involvement are shown in Table 1 . The only statistically significant differences were seen in mean albumin levels and mean 24-h proteinuria, with patients in the SH group with lower serum albumin levels (1.71 g/dL vs 3.08 g/dL; P o0.01) and more proteinuria (10.09 g/d vs 5.04 g/d; P o 0.01).
In terms of organ involvement, as expected, all patients in the SH group had renal involvement, but a significant proportion (73.17%) of WSH subjects had this as well (P = 0.02). Cardiac involvement was the next most common, with about half of patients in both groups having been diagnosed with cardiac amyloid. Autonomic nervous system and peripheral nervous system involvement were similarly distributed between both groups. SH patients were about half as likely to have soft tissue involvement compared with the WSH group, although this difference was not statistically significant. The numbers for other organ involvement were small (hepatic, gastrointestinal, musculoskeletal and pulmonary), and not statistically different between the two groups.
Peritransplantation events Peritransplantation events are listed in Table 2 . There were no significant differences in the mean number of CD34+ cells administered, mean melphalan dose given, proportion of patients receiving the full 200 mg/m 2 melphalan dose, proportion of patients requiring hospital admission or the length of hospital stay if admitted. There were also no statistically significant differences in the proportion of patients who had fever (4100.5°F), required IV antibiotics or required transfusions. More SH patients received an albumin infusion (SH 81.25% vs WSH 24.39%; P = o 0.01). Patients in both groups had similar median days to neutrophil engraftment (SH 11 days vs WSH 10 days), and identical median days to platelet engraftment (13 days for both groups).
Peritransplantation toxicity All patients in both groups developed expected grade 4 cytopenias. The proportion of patients with any grade 3 or 4 non-cytopenic adverse event during the peritransplantation period are listed in Table 3 . A larger proportion of SH patients (43.75%) had a grade 4 non-cytopenic adverse event compared with the control population (21.95%). However, the difference was not statistically significant. There was no difference in the proportion of patients who developed grade 3 non-cytopenic toxicities (68.75% of patients in the SH group and 82.93% in the WSH group).
Specific adverse events
The proportion of patients in each group with specific grade 4 and 3 adverse events are listed in Tables 3 and 4 , respectively. The most common grade 4 toxicity in patients with SH was acute kidney injury (AKI). One quarter of SH patients developed AKI compared with 5% in WSH patients (P = 0.05). All subjects with grade 4 AKI underwent hemodialysis during the peritransplantation period. However, only one patient in the SH group and one patient in the WSH group with grade 4 AKI needed long-term dialysis (6.25% vs 2.44% respectively, P = 0.49). Grade 4 hyperuricemia was the second most prevalent grade 4 toxicity in SH patients at 18.75%, compared with 5% in WSH patients, though this is not a statistically significant difference. Grade 4 hypotension was the third most common (SH 12.50% vs WSH 4.88%; P = 0.31). A higher (but not statistically significant) proportion of patients in WSH had grade 4 febrile neutropenia and infection.
The only significantly different grade 3 peritransplantation toxicity was lightheadedness, which occurred in 19% of SH patients compared with none in WSH patients (P = 0.02). The most common grade 3 adverse events in SH subjects were fatigue, pain, diarrhea, hyponatremia, hypotension and increase in alkaline phosphatase levels.
Hematologic and renal response The 6-month hematologic complete response rate was 18.75% in SH and 36.59% in WSH, but this difference was not statistically different (P = 0.54). Hematologic complete response was defined according to the 2012 consensus criteria. 13 6-month renal response rates were similar between the groups (SH 18.75% vs WSH 20.00%; P = 1.00), and was defined according to the system proposed by Palladini et al. 14 
Mortality
All patients in both groups were alive at 30 days after HDM/SCT. The 100-day mortality rate was 0% in SH patients and 2.44% in WSH patients.
DISCUSSION
This is the first study to compare the toxicity of HDM/SCT for AL amyloidosis in patients who have SH with those who do not. About one out of every five patients who were treated between January 2011 and December 2014 at our Amyloidosis Center were identified as having SH, defined as having a pretransplant serum albumin of ⩽ 2 g/dL. Our results show that patients with SH do not have more prolonged myelosuppression. Furthermore, we demonstrated that a large proportion (43.75%) of subjects with SH suffered from a grade 4 non-hematologic adverse event, double the proportion of patients in the control (WSH) group. This difference was not statistically significant. Conversely, there was a non-significant trend towards the control group having a higher grade 3 non-hematologic toxicity event rate. There were no significant differences in the 6-month hematologic complete response or renal response rates, though there was a larger trend towards a higher hematologic complete response rate in the control group. We also found that 30-and 100-day mortality was not worse in patients with SH. Only grade 4 AKI and grade 3 lightheadedness were statistically different between the two groups, with a higher proportion of SH patients suffering from these events. Grade 4 AKI is defined by the CTCAE v4 as an acute loss of renal function with life-threatening consequences requiring dialysis. Grade 3 lightheadedness is defined as severe unsteadiness or sensation of movement limiting self-care activities of daily living. AKI was the most common grade 4 toxicity in patients with SH; a quarter of these patients required initiation of hemodialysis during the peritransplantation period, compared with only 5% of patients in the control population. Remarkably, 75% of the SH patients who were initially dialyzed did not require long-term dialysis because of eventual recovery of renal function.
The incidence and outcomes of renal complications complicating HDM/SCT have previously been studied. Cornelison et al. 15 reported low rates of renal toxicity with HDM/SCT in a cohort of 75 patients with renal amyloid involvement. Only 13% of subjects in that study suffered from grade 2-3 renal toxicity, all of which was reversible. However, neither the proportion of patients with SH nor the dose of melphalan used were reported. The median pretransplant serum albumin level was 2.6 g/dL. Also, only 9% of patients had cardiac involvement. 15 Fadia et al. 16 found that peritransplantation acute renal failure occurred in 21% of 173 patients who received HDM/SCT between the years 1994 and 2000 at our institution. Five percent required initiation of dialysis, which mirrors that of our WSH population. Of note, 46% of the patients with AKI, including almost half of those who had required dialysis eventually had recovery of renal function. The authors found that bacteremia was the strongest risk factor for AKI. Other risk factors included underlying renal impairment and cardiac disease. These factors do not explain the disparate renal toxicity in our study as there were no major differences in febrile neutropenia, baseline renal function or cardiac involvement between our comparison groups. Fadia et al. 16 did not report serum albumin levels, but the degree of proteinuria (4.4 g/24 h) was less severe compared with our SH patients (10.1 g/24 h).
The most common known toxicities of HDM are profound myelosuppression, nausea and vomiting, diarrhea, and mucositis. 8 All the patients in our study had expected grade 4 cytopenias. However, none of our patients with SH suffered from grade 4 gastrointestinal toxicities. Gastrointestinal symptoms such as nausea, vomiting and diarrhea have previously been shown to Abbreviations: AKI = acute kidney injury; CHF = congestive heart failure; SH = severe hypoalbuminemia; WSH = without severe hypoalbuminemia. Abbreviations: AKI = acute kidney injury; CHF = congestive heart failure; SH = severe hypoalbuminemia; WSH = without severe hypoalbuminemia.
be a common reason for admission post HDM/SCT. 17 It is our practice to manage these gastrointestinal symptoms aggressively with IV fluids, antiemetics and antimotility agents. This may explain our low rate of severe toxicity. None of our SH patients suffered from grade 3 or 4 mucositis either. All patients undergoing HDM/SCT at our institution receive oral cryotherapy, which has been shown to decrease frequency and severity of oral mucositis. 18 The lack of mucositis in our patient population speaks to the effectiveness of this strategy.
Compared with the known common toxicities of HDM, grade 4 AKI and hypotension were in fact the more prevalent adverse events in our subjects with SH. This could be explained by the reduced oncotic pressure, decreased intravascular volume and the inability of patients to maintain their usual intravascular physiology in the face of severely low serum albumin levels. It may also be why this group of patients had more grade 3 lightheadedness. Usberti et al. 19 reported that nephrotic patients with plasma albumin concentrations o1.7 g/dL have contraction of the blood volume, along with compensatory hormonal mechanisms to promote sodium retention. This means that severe nephrotic syndrome may be a risk factor for intravascular volume depletion and AKI, especially with any stress such as diuresis or diarrhea.
The SH group in our study were three times more likely to receive an albumin infusion during the peritransplantation period; interestingly, this did not ameliorate the group's propensity for hypotension or lightheadedness. Patients with amyloid involvement of the cardiac or nervous system can also certainly suffer from more orthostasis or hypotension. 20 However, there were no significant differences in the proportion of subjects with cardiac or autonomic nervous system involvement between the groups to explain this disparate toxicity.
Melphalan's cytotoxic effects are related to its concentration and duration of exposure. 5 Therefore, the dose of melphalan received, unbound drug levels and rate of clearance of the drug can all affect the chance and severity of toxicity. Patients with higher total and unbound melphalan exposure suffer from more severe gastrointestinal toxicity and long hospital admissions. 9 Unbound drug exposure has been demonstrated to be a more sensitive predictor of both efficacy and toxicity. 9 Approximately 90% of the drug is bound to plasma proteins; 8 in vitro studies show that melphalan is 60% bound to albumin and 20% bound to alpha1-glycoprotein. 11 With such a significant amount of the drug bound to albumin, SH could in theory result in higher free melphalan levels and therefore more toxicity. Unfortunately, one of the limitations of this study was that we were unable to measure free melphalan levels.
All patients in our study received IV melphalan dosed at either 200 mg/m 2 or 140 mg/m 2 . There were no significant differences in the proportion of patients receiving the higher 200 mg/m 2 melphalan dose in either group, or the mean melphalan dose received. Melphalan has been in use for decades for various indications, 21 and is primarily given intravenously because of its known inconsistent oral absorption. 22 HDM given at 200 mg/m 2 was first adopted by the Arkansas group for multiple myeloma. It is now widely used as a preparative regimen for autologous stem cell transplantation 23 in multiple myeloma and AL amyloidosis. In multiple myeloma patients with renal failure, a lower melphalan dose of 140 mg/m 2 may have similar efficacy to the gold standard dose of 200 mg/m 2 . 24 However, in AL amyloidosis, the 200 mg/m 2 has been associated with better survival as well as better hematologic response rates compared with lower doses. 4 Dose adjustments of melphalan for age, renal function or in obese patients have not been standardized. 25 Melphalan is removed by both renal excretion and spontaneous degradation to non-cytotoxic active mono-and di-hydroxy metabolites.
9,10 Renal function is the major determinant of melphalan clearance, 9 with patients suffering from renal insufficiency having more adverse effects. 26 Although slightly more patients with SH had renal amyloid involvement in our study, the creatinine clearance (by Cockroft Gault method) was about 20% higher in this group compared with the control group, though the difference is not statistically significant.
As plasma protein binding reduces the hydrolysis rate of this drug, spontaneous degradation has a much smaller role in melphalan elimination ( o5%), 27 which may not be the case in SH. A study by Nath et al. 9 looking at population pharmacokinetics of melphalan in a group of 100 patients with multiple myeloma found that hematocrit can also affect melphalan clearance. This was thought to be a result of decreased melphalan binding to proteins in the red cell membranes. 28, 29 However, Nath et al. 9 did not detect any significant associations between unbound melphalan clearance and pretransplant paraprotein, total protein, transferrin or albumin levels. We are not able to draw any conclusions from this report because the median albumin level in the patient population of this study was 3.7 g/dL, not low as in our patients. Also, the mean hemoglobin level in our two comparison groups was identical.
Despite the proposed pharmacokinetic/pharmacodynamic differences in SH patients, no statistically significant difference in hematologic or renal response rates were seen. Bensinger et al. 30 showed that a higher preparative melphalan dose may improve response rates in myeloma; therefore, one could hypothesize that higher free melphalan levels could improve response rates in AL amyloidosis. The differences in free melphalan may not be significant enough to result in meaningful changes in response, and measuring free melphalan levels would be helpful.
In addition to what was discussed above, the retrospective nature and small sample size of this study are additional limitations. Because of small sample size, trends toward significant differences could have been missed. However, a prospective randomized study would not be possible to answer our research question. To obtain larger sample size for our SH group, we had to review data from a longer time frame (years 2011 to 2014). The data for our control population were obtained from 2011 to 2012; owing to the small sample size of the SH group, increasing control group subjects would not offer additional statistical benefit. As far as we know, the standard procedure for HDM/SCT and peritransplantation supportive care had not changed during this time period. One of the strengths of this study is that it was based on a relatively large study population for an uncommon disease, especially because we were studying a subset of patients with SH. We are also fortunate to have detailed records from our stem cell transplant database.
In conclusion, our study suggests that patients with SH receiving HDM/SCT may not require adjustment in melphalan dose for gastrointestinal toxicity, mucositis or hematologic toxicities, but patients should be informed of the higher risk of AKI. Biomarkers to predict AKI may be of value in future studies. SH was not associated with worse 30-or 100-day mortality.
